Starling Oncology, Inc.
Starling Oncology, Inc. manages community-based oncology practices through affiliated physician-owned professional corporations and contracted provider networks in the United States. Its care platform combines medical and radiation oncology, infusion services, specialty pharmacy, clinical trials, and value-based arrangements with payors and other risk-bearing entities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePhysician oncology, hematology, radiation, infusion, and supportive care delivered through community clinics.
Population-level oncology management under capitation, gain/loss sharing, and delegated contracts.
Oral oncology prescriptions dispensed through affiliated practice dispensaries to insured patients.
Clinical research administration, patient visits, and trial-related services for sponsors.
Patient education, counseling, support groups, care coordination, and related services.
Products
Reported · share of revenue- Health Care Specialty Pharmacy53.5 %
- Fee for Service29.5 %
- Capitated Revenue16.0 %
- Clinical Research Trials and Other Revenue0.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Starling primarily serves patients receiving cancer treatment through community-based oncology practices, where convenience, coordinated care, and access to subspecialized services are important. Payors, employers, managed care organizations, and other risk-bearing entities contract with Starling to manage oncology populations and pursue lower-cost, evidence-based treatment pathways. Pharmaceutical and biotechnology companies engage affiliated practices for clinical trial services, while PBMs and third-party payors reimburse specialty pharmacy prescriptions.
Receive oncology, infusion, radiation, pharmacy, counseling, and supportive care in community settings.
Purchase delegated, capitated, and shared-risk oncology management to control treatment costs and coordinate care.
Use value-based oncology arrangements intended to improve outcomes and reduce avoidable treatment spending.
Set reimbursement schedules for oral oncology drugs dispensed through affiliated practice pharmacies.
Engage affiliated practices for trial administration, patient visits, and research-related activities.
Strategy
Starling’s strategy is to scale a vertically integrated, value-based oncology model through delegated payor contracts, affiliated clinics, and managed independent providers. The company also seeks to broaden clinical and ancillary services, use acquisitions to enter new markets, and strengthen adherence to clinical pathways through provider technology. This model is intended to give Starling greater influence over physician behavior and referrals than traditional fee-for-service practices or standalone specialty benefit managers.
Delegation gives Starling responsibility for coordinating oncology care and supports recurring population-based arrangements.
A repeatable operating model can leverage existing providers before selectively building affiliated clinics.
Acquisitions can expand geographic presence while bringing independent oncologists into Starling’s value-based platform.
Ancillary services increase patient access and deepen Starling’s role across the oncology care pathway.
Digital tools are intended to improve provider engagement and compliance with evidence-based clinical pathways.
Geography
Starling operates across 17 markets and five U.S. states through 65 community-based oncology practices, affiliated professional corporations, and contracted provider networks. Its affiliated practices include operations in California, Florida, Oregon, and Texas, while the broader network includes 791 Florida providers and 11 unaffiliated California providers as of June 30, 2026. Geographic expansion relies on delegated contracts and existing provider infrastructure, while state corporate-practice-of-medicine rules influence the company’s physician-entity structure.
Risks
Starling’s growth depends on recruiting or acquiring clinics, securing payor contracts, and managing physician networks across state-specific regulatory structures. Its oncology model also depends on uninterrupted drug supply, reliable information systems, and accurate coordination of high-cost treatments. Regulatory changes, competitive pressure, weather disruptions, and adverse healthcare-industry publicity could reduce access to patients, increase compliance costs, or impair operating results.
- Payor and delegated-contract concentrationImpact: HighLikelihood: Medium
Loss, repricing, or underperformance of managed-care contracts could reduce covered lives and recurring care-management revenue.
Exposure: Health plans and risk-bearing entities
- Single-source oncology drug supplyImpact: HighLikelihood: Medium
A disruption, price increase, or logistics failure at the supplier could impair pharmacy and infusion services.
Exposure: Drug procurement and distribution
- Information technology and cybersecurity failureImpact: HighLikelihood: Medium
Clinical, billing, pharmacy, and provider-management workflows depend on company and third-party systems.
Exposure - Healthcare regulatory changeImpact: HighLikelihood: Medium
Changes affecting managed care, physician ownership, reimbursement, or marketing could increase costs or restrict operations.
Exposure: U.S. healthcare regulation and corporate-practice rules
- Dependence on clinic growth and acquisitionsImpact: HighLikelihood: Low
The expansion model requires enough affiliated practices and providers to service contracts and treat covered patients.
Exposure - Clinic disruption from external eventsImpact: MediumLikelihood: Medium
Hurricanes, floods, fires, disease outbreaks, violence, or other events can interrupt scheduling and temporarily close facilities.
Exposure: Multi-state clinic network
Accounting
Judgemental itemsRevenue is recorded when services are rendered based on coding, patient records, and identified payor responsibility.
Impact: Timing and collectability affect reported revenue and receivables.
Capitation, gain/loss sharing, and delegated contracts require estimates of covered lives, treatment costs, and contractual outcomes.
Impact: Changes in medical-cost expectations can affect revenue, provisions, and operating results.
Trial arrangements include fixed setup fees, patient-visit payments, and reimbursements recognized as research activities are performed.
Impact: Revenue timing depends on trial progress and completion of performance obligations.
Starling consolidates affiliated physician corporations when it controls relevant activities and receives substantially all economic benefits.
Impact: Consolidation brings the PCs' revenue, expenses, assets, and liabilities into reported results.
Clinic locations, equipment, acquisitions, and contingent consideration create valuation and liability-estimation requirements.
Impact: Lease liabilities, amortization, goodwill, and contingent payments can affect reported earnings and cash flow.
Similar listed companies
Publicly listed companies with a comparable business focus.
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Estrella Immunopharma, Inc.
ESLA · Biological Products, (No Diagnostic Substances)
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Astrana Health, Inc.
ASTH · Services-Management Consulting Services
Option Care Health, Inc.
OPCH · Services-Home Health Care Services
Option Care Health is a U.S.-based provider of home and alternate-site infusion services delivered through a national network of locations.
Last updated: 24/09/2026